Advertisement
AMGN vs GSK
Which Stock Would AI Choose? Amgen (AMGN) vs. GlaxoSmithKline (GSK) Stock Comparison
Key Takeaways
- GSK has outperformed AMGN year-to-date (YTD, year-to-date), gaining 11.45% compared to AMGN's 4.65%.
- GSK trades at a lower price-to-earnings (P/E) ratio of 14.42 versus AMGN's 23.92, suggesting better relative valuation.
- GSK offers a higher dividend yield at 3.27% compared to AMGN's 2.96%.
- Both stocks show mixed technical signals in recent weeks, with AMGN facing volatility ahead of Q1 earnings and GSK maintaining upward momentum.
- AMGN boasts a larger market capitalization of $183 billion versus GSK's $108 billion, reflecting its biotech focus.
- Tickeron's AI signals indicate potential undervaluation for GSK alongside strong sales growth.
Introduction
This comparison examines AMGN and GSK, two prominent players in the pharmaceutical and biotechnology sectors. Both companies deliver innovative therapeutics and vaccines, appealing to investors seeking stability in healthcare amid market volatility. Dividend-focused investors may appreciate their yields, while growth-oriented traders eye pipeline developments and earnings momentum. With upcoming Q1 results for both, this analysis highlights relative performance, valuation, and sentiment shifts in recent market activity, aiding informed decision-making in the competitive biopharma space.
AMGN Overview and Recent Performance
Amgen Inc. (AMGN) is a leading biotechnology firm specializing in human therapeutics, including blockbuster drugs like Enbrel for autoimmune diseases, Prolia for osteoporosis, and Repatha for cardiovascular risk reduction. In recent weeks, AMGN stock has traded around $340, within a 52-week range of $261 to $391. Year-to-date gains stand at 4.65%, but the shares have shown volatility, including a recent slide amid broader market rises and anticipation of Q1 earnings on April 30. Factors influencing sentiment include analyst previews projecting $4.73 EPS and $8.49 billion in revenue, alongside news of a proposed FDA withdrawal for Tavneos and positive notes on AI leadership changes. Technical signals from Tickeron suggest an upward trend despite mixed bullish and bearish indicators.
GSK Overview and Recent Performance
GSK plc (GSK), formerly GlaxoSmithKline, focuses on vaccines, specialty medicines for oncology and immunology, and general therapies for respiratory conditions. The stock recently hovered near $54, with a 52-week range from $35 to $62. It has delivered stronger YTD performance at 11.45%, buoyed by robust 2025 results and reaffirmed growth outlooks of 3-5% turnover in 2026. Recent market activity reflects upward momentum, with an earnings call scheduled for April 29. Sentiment benefits from strong sales growth and pipeline progress in areas like shingles and RSV vaccines, though technicals show some bearish crossovers like MACD turning negative. Tickeron's analysis highlights undervaluation and a profitable business model.
Trending AI Robots
Tickeron's Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available—specifically 25 selected out of 351 total. These bots employ diverse strategies, including signal agents, virtual agents, and brokerage agents, trading thousands of tickers across various timeframes. Performance stats vary widely, with annualized returns ranging from 50% to over 170%, win rates of 50-75%, and profit factors between 1.5 and 4.5. Tailored to current market conditions, they offer short-term patterns, long-term trends, and risk-adjusted approaches. Investors can explore these bots to enhance strategies amid volatile conditions in stocks like AMGN and GSK; visit the page to review and deploy suitable options.
Head-to-Head Comparison
Amgen and GSK operate in overlapping biopharma domains but diverge in focus: AMGN emphasizes high-margin biotech drugs with innovation-driven growth, while GSK balances vaccines and general medicines for steadier revenue. Valuation favors GSK's lower P/E (14.42 vs. 23.92), implying less premium for earnings, though AMGN's larger $183 billion market cap underscores scale. Dividend seekers prefer GSK's 3.27% yield over AMGN's 2.96%. Recent momentum tilts to GSK's YTD gains and sales strength, contrasting AMGN's earnings volatility and regulatory hurdles. Risk factors include pipeline dependencies for both, with AMGN facing patent cliffs and GSK currency exposure as a UK-based firm. Sector exposure aligns in healthcare, but market sentiment views GSK as undervalued with lower risk-high return potential per Tickeron ratings.
Tickeron AI Verdict
Tickeron's AI currently leans toward GSK based on its undervaluation signals, stronger YTD momentum, and robust sales model amid recent uptrends. AMGN shows promise in biotech catalysts and trend consistency but trails in relative positioning and P/E attractiveness. Probabilistic factors like GSK's profit-risk rating suggest higher near-term favorability, though both warrant monitoring post-earnings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Hold and GSK is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 3 FA rating(s) are green whileGSK’s FA Score has 2 green FA rating(s).
- AMGN’s FA Score: 3 green, 2 red.
- GSK’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 3 TA indicator(s) are bullish while GSK’s TA Score has 3 bullish TA indicator(s).
- AMGN’s TA Score: 3 bullish, 6 bearish.
- GSK’s TA Score: 3 bullish, 5 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а -4.65% price change this week, while GSK (@Pharmaceuticals: Major) price change was -4.14% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.18%. For the same industry, the average monthly price growth was +8.31%, and the average quarterly price growth was +2.32%.
Reported Earning Dates
AMGN is expected to report earnings on Jul 30, 2026.
GSK is expected to report earnings on Jul 28, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.18% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| AMGN | GSK | AMGN / GSK | |
| Capitalization | 182B | 103B | 177% |
| EBITDA | 16.7B | 10.1B | 165% |
| Gain YTD | 4.643 | 5.106 | 91% |
| P/E Ratio | 23.49 | 13.28 | 177% |
| Revenue | 37.2B | 32.8B | 113% |
| Total Cash | 12B | 3.44B | 349% |
| Total Debt | 57.3B | 19.1B | 300% |
AMGN | GSK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 71 | 13 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 28 | 41 | |
SMR RATING 1..100 | 12 | 27 | |
PRICE GROWTH RATING 1..100 | 52 | 51 | |
P/E GROWTH RATING 1..100 | 64 | 80 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (6) in the Biotechnology industry is in the same range as GSK (15) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to GSK’s over the last 12 months.
AMGN's Profit vs Risk Rating (28) in the Biotechnology industry is in the same range as GSK (41) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to GSK’s over the last 12 months.
AMGN's SMR Rating (12) in the Biotechnology industry is in the same range as GSK (27) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to GSK’s over the last 12 months.
GSK's Price Growth Rating (51) in the Pharmaceuticals Major industry is in the same range as AMGN (52) in the Biotechnology industry. This means that GSK’s stock grew similarly to AMGN’s over the last 12 months.
AMGN's P/E Growth Rating (64) in the Biotechnology industry is in the same range as GSK (80) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to GSK’s over the last 12 months.
| AMGN | GSK | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 3 days ago 47% | 3 days ago 46% |
| Momentum ODDS (%) | 3 days ago 53% | 3 days ago 43% |
| MACD ODDS (%) | 3 days ago 54% | 3 days ago 56% |
| TrendWeek ODDS (%) | 3 days ago 54% | 3 days ago 53% |
| TrendMonth ODDS (%) | 3 days ago 57% | 3 days ago 58% |
| Advances ODDS (%) | 9 days ago 56% | 9 days ago 61% |
| Declines ODDS (%) | 3 days ago 52% | 3 days ago 54% |
| BollingerBands ODDS (%) | 3 days ago 50% | 3 days ago 78% |
| Aroon ODDS (%) | 3 days ago 52% | 3 days ago 39% |
Advertisement
GSK and
Correlation & Price change
A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.